These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 6329589)

  • 1. Review of naltrexone, a long-acting opiate antagonist.
    Crabtree BL
    Clin Pharm; 1984; 3(3):273-80. PubMed ID: 6329589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.
    Verebey K
    NIDA Res Monogr; 1981; 28():147-58. PubMed ID: 6791001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone: a clinical perspective.
    Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.
    Porter SJ; Somogyi AA; White JM
    Addict Biol; 2002 Apr; 7(2):219-25. PubMed ID: 12006217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sequential use of clonidine and naltrexone in the treatment of opiate addicts.
    Gold MS; Dackis CA; Washton AM
    Adv Alcohol Subst Abuse; 1984; 3(3):19-39. PubMed ID: 6388273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naltrexone in addicted business executives and physicians.
    Washton AM; Pottash AC; Gold MS
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):39-41. PubMed ID: 6088468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM; Glass WJ
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.
    Meyer MC; Straughn AB; Lo MW; Schary WL; Whitney CC
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):15-9. PubMed ID: 6469932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone treatment in a jail work-release program.
    Brahen LS; Henderson RK; Capone T; Kordal N
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):49-52. PubMed ID: 6469937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.
    Arch Gen Psychiatry; 1978 Mar; 35(3):335-40. PubMed ID: 365122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ultra-rapid detoxification of opiate dependent patients: review of the literature, critiques and proposition for an experimental protocol].
    Fontaine E; Godfroid IO; Guillaume R
    Encephale; 2001; 27(2):187-93. PubMed ID: 11407272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of naltrexone treatment.
    O'Brien CP; Greenstein R; Woody GE
    NIDA Res Monogr; 1978; (19):315-20. PubMed ID: 218107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone disposition in man after subcutaneous administration.
    Wall ME; Perez-Reyes M; Brine DR; Cook CE
    Drug Metab Dispos; 1984; 12(6):677-82. PubMed ID: 6150815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing of drug delivery systems for use in the treatment of narcotic addiction.
    Reuning RH; Malspeis L; Frank S; Notari RE
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):43-5. PubMed ID: 827709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effects of naltrexone in 155 heroin ex-addicts.
    Volavka J; Resnick RB; Kestenbaum RS; Freedman AM
    Biol Psychiatry; 1976 Dec; 11(6):679-85. PubMed ID: 999987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
    Foster J; Brewer C; Steele T
    Addict Biol; 2003 Jun; 8(2):211-7. PubMed ID: 12850780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with naltrexone in suburban opioid addicts.
    Tennant FS; Rawson RA; Cohen AJ; Mann A
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):42-5. PubMed ID: 6469935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naltrexone double blind placebo controlled study in Israel.
    Lerner A; Sigal M; Bacalu A; Shiff R; Burganski I; Gelkopf M
    Isr J Psychiatry Relat Sci; 1992; 29(1):36-43. PubMed ID: 1568861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.